Topographic heterogeneity of amyloid B-protein epitopes in brains with various forms of neuronal ceroid lipofuscinoses suggesting defective processing of amyloid precursor protein.
To verify our hypothesis of defective protease inhibitor domains that are encoded by abnormal processing of amyloid precursor protein (APP) in brains of patients with neuronal ceroid lipofuscinoses (NCL), immunohistochemical and cytochemical studies were performed with monoclonal antibodies (mAbs) directed against various domains of APP. For the studies, 22 autopsy brains were used: 12 with different forms of NCL, and 10 control brains. The staining procedure for the avidin-biotin complex (ABC) technique and the postembedding gold-labelled procedure for electron microscopy (EM) were employed. Of all mAbs used for the study, only mAbs generated against amyloid B-protein bound to neural tissue were affected with NCL. The strongest immunostaining of neurons and of some reactive glial cells was found in brains with the juvenile form of NCL. Only in the infantile form of the disease were some neurons overloaded with storage material weakly immunoreactive. In brains of patients with the adult form of NCL, immunoreactivity was found in affected neurons and in extracellularly deposited material of senile plaques. The results of EM study showed that the immunoreactivity was restricted to lysosomal cytosomes in neural tissue with any form of NCL selectively localized on the curvilinear and fingerprint proteinaceous component of ceroid lipofuscin. Studies performed on control aging brains and Alzheimer's disease (AD) brains confirmed previous observations of immunoreactivity being found diffusely in the protein component of some neurons containing lipopigment.(ABSTRACT TRUNCATED AT 250 WORDS)
New York State Office of Mental Retardation and Developmental Disabilities, Institute for Basic Research, Staten Island 10314.
K E
KE
Wisniewski
D
D
Maslinska
T
T
Kitaguchi
K S
KS
Kim
H H
HH
Goebel
M
M
Haltia
D000293:Adolescent; D000328:Adult; D000368:Aged; D000682:Amyloid / Q000276:immunology / Q000378:metabolism*; D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D000939:Epitopes; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008875:Middle Aged; D009472:Neuronal Ceroid-Lipofuscinoses / Q000378:metabolism* / Q000473:pathology; D011499:Protein Processing, Post-Translational
D000682:Amyloid; D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D000939:Epitopes